All of the major dermal fillers either have lidocaine already or will soon have it, so AGN’s FDA approval of Juvederm with lidocaine was important from a competitive standpoint.
-- p.s. Merz’s acquisition of BFRM closes this week. Here’s a question to ponder: Will Merz now become a buyout target in its own right? I originally thought JNJ would end up owning BFRM at some point and they still could—by buying Merz.
Apropos to nothing in particular…this plastic surgeon is carrying off-label use of dermal fillers and botulinum toxin to a new level by performing pseudo nose jobs: